Market Access News | pharmaphorum

News

scientifically visualization of a coronavirus spike protein

Merck kicks off oral COVID-19 antiviral filing in Canada

Health Canada has started a rolling review of Merck & Co's molnupiravir, an oral antiviral therapy treatment for COVID-19 partnered with Ridgeback Biotherapeutics.

News

Ipsen hit by new palaver for rare disease drug palovarotene

Just as Ipsen's $1 billion bet on rare bone disease drug palovarotene seemed to be nearing the finish line, it has fallen at the final hurdle.

News

US health insurer will not fund Biogen, Eisai's Alzheimer's ...

Health insurer Excellus BlueCross BlueShield has said it will not cover treatment with Biogen and Eisai's new Alzheimer's disease drug Aduhelm because it has not been shown to be medically

News

NICE changes stance on Lilly's breast cancer dug Verzenios

After rejecting Eli Lilly's Verzenios for breast cancer therapy earlier this year, NICE has relented, recommending the drug for routine NHS use alongside hormonal therapy fulvestrant.

News

Red blood cells moving in blood vessels with depth of field.

FDA rejects FibroGen/AZ's roxadustat, asking for new trial

The FDA has demanded another clinical trial of FibroGen and AstraZeneca's roxadustat for anaemia caused by chronic kidney disease (CKD) before it will consider approval, setting up a length

News

Axsome faces delay for depression drug, hitting shares hard

The FDA was supposed to be delivering its verdict on Axsome Therapeutics' depression therapy AXS-05 in less than a fortnight – but instead has delivered the company a letter outlining defic

Merck kicks off oral COVID-19 antiviral filing in Canada

Ipsen hit by new palaver for rare disease drug palovarotene

US health insurer will not fund Biogen, Eisai's Alzheimer's ...

NICE changes stance on Lilly's breast cancer dug Verzenios

FDA rejects FibroGen/AZ's roxadustat, asking for new trial

Axsome faces delay for depression drug, hitting shares hard

Datroway joins Trodelvy for frontline TNBC in the EU

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks